振东制药调整回购价格上限至11.4元/股

Group 1 - The core point of the news is that Shanxi Zhendong Pharmaceutical Co., Ltd. has adjusted the upper limit of its share repurchase price from 6.00 yuan per share to 11.4 yuan per share to ensure the effective execution of the repurchase plan in the current market environment [2][3] - The initial repurchase plan announced on October 24, 2024, aimed to use a total fund of "not less than 50 million yuan and not more than 100 million yuan" to repurchase shares at a price not exceeding 6 yuan per share within 12 months after the shareholders' meeting approval [2] - The adjustment in the repurchase price was driven by the company's stock price consistently exceeding the original upper limit, necessitating a revision to facilitate the continuation of the repurchase operations [2] Group 2 - The company has already repurchased a total of 12.9167 million shares, accounting for 1.28% of the current total share capital as of the announcement date [3] - The management's decision to raise the repurchase price reflects their strong confidence in the company's future stable development and intrinsic value, aiming to protect shareholder interests [3] - In recent years, the company has been actively expanding its business layout, particularly in the innovative drug research and development sector, with product coverage in oncology, dermatology, and gynecology [2]